Evolent Health, Inc. Cash Flow Statement
EVH|11 years of annual SEC 10-K data (FY2015-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 11 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Operating Cash Flow
$39M
FY2025
Free Cash Flow
N/A
FY2025
Capital Expenditures
N/A
Cash used for long-term assets
Dividends Paid
N/A
FY2025
Evolent Health, Inc. generated $39M in operating cash flow in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -0.84 (distress zone, below 1.23 threshold)
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
- Negative return on equity: -15.6% ROE
- High leverage: Debt-to-equity ratio of 2.34
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$64.6M | -$61.6M | -$113.0M | -$19.2M | -$37.6M | -$334.2M | -$302.0M | -$52.7M | -$60.7M | -$159.7M | $332.5M |
| Depreciation & Amortization | $115.9M | $118.4M | $123.4M | $67.2M | $60.0M | $61.5M | $60.9M | $44.5M | $32.4M | $17.2M | $7.2M |
| Operating Cash Flow | $38.8M | $18.8M | $142.6M | -$11.6M | $38.7M | -$16.2M | -$42.6M | -$20.7M | -$28.0M | -$35.5M | -$18.5M |
| Capital Expenditures | - | - | - | - | - | - | $35.5M | $39.5M | $27.8M | $15.5M | $6.5M |
| Free Cash Flow | - | - | - | - | - | - | -$78.2M | -$60.2M | -$55.8M | -$51.0M | -$25.0M |
| Share Buybacks | $40.0M | $0 | $0 | - | - | - | - | - | - | - | - |
| FCF Margin | - | - | - | - | - | - | -11.4% | -9.6% | -12.8% | -20.1% | -25.8% |